NCT01726517View on ClinicalTrials.gov

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2014

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG

LDV/SOF

LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

DRUG

RBV

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (1)

78215

San Antonio